Compare ClearPoint Neuro Inc (CLPT) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Freshworks Inc — how do they compare? ClearPoint Neuro Inc trades at $14.99 (market cap $454.21M), while Freshworks Inc trades at $11.74 (market cap $3.31B). The key difference: Freshworks Inc is far larger — about 7.3× ClearPoint Neuro Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | FRSH | |
|---|---|---|
Market Cap | $454.21M | $3.31B |
Sector | Health | Technology |
52-Week High | $29.60 | $13.97 |
52-Week Low | $8.66 | $6.88 |
Enterprise Value | $488.79M | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Freshworks (FRSH) trades at $11.98, up 1.18% with bullish technical signals and strong fundamentals. The company reported Q2 2026 revenue growth of 16% year-over-year, achieving its first GAAP profitability quarter with $3.2 million net income. Recent FedRAMP designation and Gartner leadership recognition highlight strategic progress. Analyst consensus shows 50% buy ratings with a $16.50 price target, suggesting 38% upside potential.
The outlook remains positive with accelerating revenue growth and improved profitability, though elevated P/E and EV/EBITDA ratios warrant caution. Key risks include competitive pressures in SaaS and execution challenges. Current momentum supports continued appreciation toward analyst targets, making FRSH attractive for growth-oriented investors despite valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
